Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Nat Commun. 2019 Jul 30;10(1):3298. doi: 10.1038/s41467-019-10914-6.
Gastric acid suppression promotes allergy in mechanistic animal experiments and observational human studies, but whether gastric acid inhibitors increase allergy incidence at a population level remains uncharacterized. Here we aim to assess the use of anti-allergic medication following prescription of gastric acid inhibitors. We analyze data from health insurance records covering 97% of Austrian population between 2009 and 2013 on prescriptions of gastric acid inhibitors, anti-allergic drugs, or other commonly prescribed (lipid-modifying and antihypertensive) drugs as controls. Here we show that rate ratios for anti-allergic following gastric acid-inhibiting drug prescriptions are 1.96 (95%CI:1.95-1.97) and 3.07 (95%-CI:2.89-3.27) in an overall and regional Austrian dataset. These findings are more prominent in women and occur for all assessed gastric acid-inhibiting substances. Rate ratios increase from 1.47 (95%CI:1.45-1.49) in subjects <20 years, to 5.20 (95%-CI:5.15-5.25) in > 60 year olds. We report an epidemiologic relationship between gastric acid-suppression and development of allergic symptoms.
在机制动物实验和观察性人类研究中，胃酸抑制促进过敏，但胃酸抑制剂是否会在人群水平上增加过敏发生率尚不清楚。在这里，我们旨在评估在开具胃酸抑制剂后使用抗过敏药物的情况。我们分析了 2009 年至 2013 年期间覆盖奥地利 97%人口的健康保险记录中的数据，这些记录包括开具胃酸抑制剂、抗过敏药物或其他常用药物（调脂药和降压药）的处方作为对照。结果显示，在奥地利的总体和地区数据集内，使用抗过敏药物的比率比值（RR）在使用胃酸抑制剂后为 1.96（95%CI：1.95-1.97）和 3.07（95%-CI：2.89-3.27）。这些发现女性更为明显，且所有评估的胃酸抑制剂均有此结果。RR 从<20 岁的 1.47（95%CI：1.45-1.49）增加到>60 岁的 5.20（95%-CI：5.15-5.25）。我们报告了胃酸抑制与过敏症状发展之间的流行病学关系。
